Market Place
Sourcing Support
Eagle Provides Update on Nasdaq Delisting and SEC Deregistration
15 Nov 2024 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Adopts Limited Duration Stockholder Plan
31 Oct 2024 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
27 Aug 2024 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
22 May 2024 //
GLOBENEWSWIRE
Eagle Pharma TiP on Pedia IV Amisulpride PONV Ph2/3 at SAMBA 2024
30 Apr 2024 //
GLOBENEWSWIRE
Eagle: Sustained Amisulpride PONV Response At ASPAN 2024
15 Apr 2024 //
GLOBENEWSWIRE
Eagle Pharma Receives Nasdaq Deficiency For Late 10-K Filing
12 Apr 2024 //
GLOBENEWSWIRE
EGRX Investors Have Opportunity to Lead Eagle Pharm Securities Fraud Lawsuit
08 Feb 2024 //
PR NEWSWIRE
EGRX Investors Have Opportunity to Lead Eagle Pharma Securities Fraud Lawsuit
25 Jan 2024 //
PR NEWSWIRE
Eagle Pharma Provides Update on Bendamustine Intellectual Property Portfolio
18 Jan 2024 //
GLOBENEWSWIRE
Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride
06 Dec 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Announces Management Change
29 Nov 2023 //
GLOBENEWSWIRE
Eagle Pharmac Announces Receipt of Notification of Deficiency from Nasdaq
29 Nov 2023 //
GLOBENEWSWIRE
Eagle Delays Third Quarter 2023 Results and Conference Call
09 Nov 2023 //
GLOBENEWSWIRE
Eagle to Host Third Quarter 2023 Financial Results on November 9, 2023
08 Nov 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Granted Patent for PEMFEXY®
24 Oct 2023 //
GLOBENEWSWIRE
Eagle Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS
23 Oct 2023 //
GLOBENEWSWIRE
Eagle Pharma Awarded First Prize for Poster to Be Presented at Annual Meeting
04 Oct 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023
19 Sep 2023 //
GLOBENEWSWIRE
Eagle to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference
11 Sep 2023 //
GLOBENEWSWIRE
NDA Submission Planned EA-114 in Metastatic Breast Cancer Following +ve Type C
30 Aug 2023 //
ONCLIVE
Eagle to Present BYFAVO® (remimazolam) for Injection Abstract a
30 Aug 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Announces Positive Type C Meeting with FDA for EA-114
29 Aug 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
22 Aug 2023 //
GLOBENEWSWIRE
Eagle Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ Guidance
17 Aug 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Reports Second Quarter 2023 Results
08 Aug 2023 //
GLOBENEWSWIRE
Eagle Pharma to Host Second Quarter 2023 Financial Results on August 8, 2023
01 Aug 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Raises 2023 Adjusted non-GAAP EPS¹ Guidance
31 Jul 2023 //
GLOBENEWSWIRE
Eagle Pharma Announces First Patient Randomized in Ph 2 Study Evaluating CAL02
24 Jul 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance
15 Jun 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Receives FDA QIDP and Fast-Track Designation for CAL02
14 Jun 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Announces Acceptance of Two Abstracts at SAEM Meeting
11 May 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Reports First Quarter 2023 Results
09 May 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Granted Unique J-Code for Byfavo®
01 May 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals to Host 1Q 2023 FYR on May 9, 2023
27 Apr 2023 //
GLOBENEWSWIRE
Eagle Pharma Reaches Settlement Agreement with Dr. Reddy`s Laboratories Inc.
05 Apr 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
13 Mar 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals to Present at the Barclays Global Healthcare Conference
09 Mar 2023 //
GLOBENEWSWIRE
Eagle to Host Fourth Quarter and Full Year 2022 Financial Results
03 Mar 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Provides Business Update and Guidance for 2023
10 Jan 2023 //
GLOBENEWSWIRE
Eagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare
21 Dec 2022 //
GLOBENEWSWIRE
Eagle Receives FDA Approval for Additional Indication for PEMFEXY
19 Dec 2022 //
GLOBENEWSWIRE
Eagle Pharma Reaches Settlement Agreement with Accord Related to BENDEKAÂ
12 Dec 2022 //
GLOBENEWSWIRE
Eagle Pharma Investor Day to Focus on Acute Care Products and Pipeline Programs
01 Dec 2022 //
GLOBENEWSWIRE
Eagle Pharma Announces FDA Acceptance of IND Application for CAL02
14 Nov 2022 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Reports Third Quarter 2022 Results
07 Nov 2022 //
GLOBENEWSWIRE
Eagle Pharma to Host Third Quarter 2022 Financial Results on November 7, 2022
31 Oct 2022 //
GLOBENEWSWIRE
T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results
12 Oct 2022 //
GLOBENEWSWIRE
Eagle and Enalare Therapeutics Announce FDA Orphan Drug Designation for ENA-001
03 Oct 2022 //
GLOBENEWSWIRE
Eagle Pharma, Enalare receive additional award worth up to $50 mn from BARDA
29 Sep 2022 //
PHARMABIZ
Eagle and Enalare Therapeutics Announce Additional Award Worth Up to $50 M
27 Sep 2022 //
GLOBENEWSWIRE
New Jersey biotech nets $50M+ BARDA contract for respiratory candidate
27 Sep 2022 //
ENDPTS
Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Conference
30 Aug 2022 //
GLOBENEWSWIRE
Endo loses appeal challenging generic version of best-seller Vasostrict
19 Aug 2022 //
REUTERS
Federal Circuit Rules in Favor of Eagle Pharma in Vasopressin Litigation
18 Aug 2022 //
GLOBENEWSWIRE
Eagle Pharma Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics
09 Aug 2022 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Reports Second Quarter 2022 Results
09 Aug 2022 //
GLOBENEWSWIRE
Eagle Pharma to Host Second Quarter 2022 Financial Results on August 9, 2022
28 Jul 2022 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial
18 Jul 2022 //
GLOBENEWSWIRE
Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group
09 Jun 2022 //
GLOBENEWSWIRE
